Loading organizations...
§ Venture Capital · Encinitas, CA, USA
Venture builder forming and developing biotechnology, pharmaceutical, diagnostic, and medical device companies.
Hale BioPharma Ventures is a San Diego, California-based private company specializing in the formation, development, and launch of biotechnology, specialty pharmaceutical, diagnostic, and medical device companies. The firm functions as a venture builder and incubator, with its leadership actively involved in founding and developing new life science ventures from inception through commercialization. It has been instrumental in the founding and development of over a dozen successful biotechnology and specialty pharmaceutical companies, generating returns through their eventual sale or public offering. Recognizable ventures include Oncternal Therapeutics (NASDAQ: ONCT), Neurelis, Biocept, Somaxon Pharmaceuticals, and SkinMedica. Leadership maintains board positions and advisory roles across its portfolio, reflecting a hands-on development approach. David F. Hale, a prominent figure in the San Diego biotech sector, established Hale BioPharma Ventures in 2006.
Hale BioPharma Ventures has 1 tracked investment across 1 company. The latest tracked deal is $15.0M Series B in Colorescience in September 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2014 | Colorescience | $15.0M Series B | Longwood Fund | 5AM Ventures, Avalon Ventures, Bain Capital Life Sciences, Domain Associates, OrbiMed, Osage University Partners, Pivotal BioVenture Partners, Rivervest, Heather Preston, HealthCare Ventures, Split Rock Partners |